ClinicalTrials.gg
CompletedNCT00547248Updated Jan 14, 2019Results posted

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

A Phase 3 interventional study of Synflorix and Tritanrix-HepB in Infections, Streptococcal, sponsored by GlaxoSmithKline. Completed at 7 sites in 2 countries. Open to participants aged 12 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
756
Allocation
Randomized
Ages
12 Months to 18 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing PHiD-CV vaccine in Streptococcal Infections — none open to participants now, none under way, none of them phase 3. PHiD-CV vaccine · Streptococcal Infections.

Enrollment
5th of 25
756 · median 360
Started
2007
with 3 others
Phase 3
24 of 25
none open now
Registered
5th of 25
by date
Lead sponsor
25 of 25
GlaxoSmithKline

Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, this one is the 5th largest by enrollment, is one of 4 that started in 2007, is one of 24 in phase 3, and was the 5th registered.

Streptococcal Infections

147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.

Browse Streptococcal Infections studies →

Open to participants now

None of the 25 studies testing PHiD-CV vaccine in Streptococcal Infections is open now. The open studies under Streptococcal Infections, anywhere →

About PHiD-CV vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 12 Months to 18 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing PHiD-CV vaccine in Streptococcal Infections as a file.
02

Study summary

The purpose of this observer blind study is to assess the safety in terms of fever >39°C (rectal temperature) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK 1024850A at 12 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined vaccine and OPV or IPV vaccines. Subjects participating in this study should have received three doses of pneumococcal conjugate vaccine in the primary study.

This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00344318)

Read the detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007

03

Conditions studied

  • Infections, Streptococcal

Keywords

  • Booster vaccination.
  • Immunogenicity
  • Pneumococcal vaccine
  • Safety
  • Pneumococcal disease
04

Who can participate

Ages eligible
12 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 12-18 months of age at the time of the booster vaccination and who previously participated in study 107007 and received three doses of pneumococcal conjugate vaccine.
  • Written obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Concurrently participating in another clinical study, at any time during the study period (active phase and extended safety follow-up), in which the subject has been or will be exposed to an or a non-investigational product (pharmaceutical product or device).
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within one month preceding the booster dose of study vaccines, or planned use during the entire study period
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs within 6 months prior to the booster dose of study vaccines.
  • Planned administration/administration of a vaccine not foreseen by the study protocol, during the period starting one month before the booster dose of study vaccines and up to the follow-up visit.
  • Administration of any pneumococcal, diphtheria, tetanus, pertussis, polio, , Haemophilus influenzae type b vaccine other than the study vaccines from study 107007.
  • History of, or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b diseases.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or progressive neurological disease.
  • Acute disease at the time of enrolment.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
  • A family history of congenital or hereditary immunodeficiency.
  • Major congenital defects or serious chronic illness.
  • Administration of immunoglobulins and/or any blood products within three months preceding the booster dose of study vaccines or planned administration during the active phase of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
756 participants (actual)

Study arms

  • Experimental
    Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group

    Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.

    Biological: Synflorix · Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Polio Sabin

  • Active comparator
    Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group

    Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.

    Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Polio Sabin · Biological: Prevenar (Wyeth)

  • Experimental
    Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group

    Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.

    Biological: Synflorix · Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Poliorix

  • Active comparator
    Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group

    Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.

    Biological: Tritanrix-HepB · Biological: Hiberix · Biological: Poliorix · Biological: Prevenar (Wyeth)

Interventions

  • BiologicalSynflorix

    Intramuscular injection, 1 dose

    Also known as: Pneumococcal conjugate vaccine GSK1024850A

  • BiologicalTritanrix-HepB

    Drug page: Diphtheria-Tetanus-Pertussis Vaccine

    Intramuscular injection, 1 dose

    Also known as: DTPw-HBV vaccine

  • BiologicalHiberix

    Reconstituted with Tritanrix-Hep B before injection

    Also known as: Hib vaccine

  • BiologicalPolio Sabin

    Oral, 1 dose

    Also known as: OPV

  • BiologicalPoliorix

    Intramuscular injection, 1 dose

    Also known as: IPV

  • Intramuscular injection, 1 dose

    Also known as: Pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off

    Fever was measured as rectal temperature. The cut-off was 39.0 degree Celsius (°C). Assessment of occurrences of fever \> 39.0 (°C) was performed after booster vaccination with Synflorix™ or Prevenar™ vaccines.

    Time frame: Within the 4-day (Days 0-3) period after booster vaccination

Secondary outcomes

  1. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Solicited local symptoms assessed included pain, redness and swelling. "Any" was defined as incidence of the specified symptom regardless of intensity. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm).

    Time frame: Within the 4-day (Days 0-3) period after booster vaccination

  2. Number of Subjects With Any and Grade 3 Solicited General Symptoms

    Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature greater than or equal to (≥) 38.0°C), irritability, and loss of appetite."Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) \>40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all.

    Time frame: Within the 4-day (Days 0-3) period after booster vaccination

  3. Number of Subjects With Unsolicited Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

    Time frame: Within the 31-day (Days 0-30) period after booster vaccination

  4. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

    Time frame: Throughout the active phase of the study (Month 0 to Month 1)

  5. Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off

    The cut-off was 0.20 microgram per milliliter (μg/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  6. Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations

    Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  7. Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

    Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  8. Antibody Concentrations to Protein D (Anti-PD)

    Seropositivity status, defined as anti-PD antibody concentrations ≥100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  9. Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A

    Seropositivity status, defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  10. Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A

    Seropositivity status, defined as Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  11. Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off

    The cut-off of the assay was 0.05 μg/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  12. Number of Subjects With Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off

    The cut-off for the assay was 8.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  13. Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off

    The cut-of for the assay was 0.05 μg/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  14. Number of Subjects With Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A ≥ the Cut-off

    The cut-off for the assay was 8.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  15. Number of Subjects With Antibody Concentrations Against Protein D (Anti-PD) ≥ the Cut-off

    The cut-off for the assay was 100 ELISA units per milliliter (EL.U/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  16. Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations

    Seroprotection status, defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  17. Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations

    Seroprotection status, defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  18. Anti-Bordetella Pertussis (BPT) Antibody Concentrations

    Seropositivity status, defined as anti-BPT antibody concentrations ≥ 15 EL.U/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  19. Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations

    Seroprotection status, defined as anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  20. Anti-polio Type 1, 2 and 3 Antibody Titers

    Seroprotection status, defined as anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers ≥ 8.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  21. Number of Subjects With Anti-Bordetella Pertussis (BPT) With Concentrations ≥ the Cut-off

    The cut-off for the assay was 15 EL.U/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  22. Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations ≥ the Cut-off

    The cut-off for the assay was 0.1 milli-international units per milliliter (mIU/mL).

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  23. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off

    The cut-off for the assay was 0.15 μg/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  24. Number of Subjects With Anti-PRP Antibody Concentration ≥ the Cut-off

    The cut-off for the assay was 1.0 μg/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  25. Number of Subjects With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off

    The cut-off for the assay was 10 mIU/mL.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  26. Number of Subjects With Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers ≥ the Cut-off

    The cut-off for the assay was 8.

    Time frame: Prior to (Month 0) and one month after booster vaccination (Month 1)

  27. Number of Subjects With Vaccine Response to Anti-Bordetella Pertussis (BPT)

    Vaccine response for anti-BPT, defined as the appearance of antibodies in subjects seronegative at pre-vaccination, or at least 2-fold increase of pre-vaccination antibody concentrations in those who were initially seropositive at pre-vaccination.

    Time frame: One month after booster vaccination (Month 1)

07

Results

Posted Jan 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Started2809328598
Completed2809327596
Not completed00102
Withdrew: Protocol violation0011
Withdrew: Migrated/moved from study area0020
Withdrew: Withdrawal by subject0071

Outcome measures

PrimaryNumber of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off

Fever was measured as rectal temperature. The cut-off was 39.0 degree Celsius (°C). Assessment of occurrences of fever \> 39.0 (°C) was performed after booster vaccination with Synflorix™ or Prevenar™ vaccines.

Time frame:
Within the 4-day (Days 0-3) period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off
ParticipantsSynflorix Pooled GroupPrevenar Pooled Group
Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off6420
Statistical analysis
  • Synflorix Pooled Group vs Prevenar Pooled Group · Philips' statistical test · Difference in percentage: 0.89 · 95% CI -4.82 to 5.59
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Solicited local symptoms assessed included pain, redness and swelling. "Any" was defined as incidence of the specified symptom regardless of intensity. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm).

Time frame:
Within the 4-day (Days 0-3) period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Any Pain2036624877
Grade 3 Pain402011739
Any Redness1073719766
Grade 3 Redness833511
Any Swelling923215852
Grade 3 Swelling219348
SecondaryNumber of Subjects With Any and Grade 3 Solicited General Symptoms

Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature greater than or equal to (≥) 38.0°C), irritability, and loss of appetite."Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) \>40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all.

Time frame:
Within the 4-day (Days 0-3) period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited General Symptoms
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Any Drowsiness903219066
Grade 3 Drowsiness5172
Any Fever1385121565
Grade 3 Fever0010
Any Irritability1736424379
Grade 3 Irritability123405
Any Loss of appetite972818457
Grade 3 Loss of appetite81131
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

Time frame:
Within the 31-day (Days 0-30) period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Number of Subjects With Unsolicited Adverse Events (AEs)25910635
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

Time frame:
Throughout the active phase of the study (Month 0 to Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Number of Subjects With Serious Adverse Events (SAEs)2052
SecondaryNumber of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off

The cut-off was 0.20 microgram per milliliter (μg/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-1, Month 01002642
Anti-1, Month 113631252
Anti-4, Month 0113257823
Anti-4, Month 11364312543
Anti-5, Month 01187983
Anti-5, Month 113681243
Anti-6B, Month 0113249027
Anti-6B, Month 11344212241
Anti-7F, Month 012871181
Anti-7F, Month 113691251
Anti-9V, Month 01324011642
Anti-9V, Month 11364312543
Anti-14, Month 01264211140
Anti-14, Month 11354312543
Anti-18C, Month 01303611135
Anti-18C, Month 11364312543
Anti-19F, Month 01291112122
Anti-19F, Month 11364312343
Anti-23F, Month 0123328940
Anti-23F, Month 11354212342
SecondaryAnti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations

Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · μg/mL
Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations
μg/mLSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-1, Month 00.35 (0.29 to 0.42)0.03 (0.03 to 0.04)0.19 (0.16 to 0.22)0.04 (0.03 to 0.05)
Anti-1, Month 110.8 (9.22 to 12.66)0.04 (0.03 to 0.05)2.14 (1.8 to 2.55)0.04 (0.03 to 0.05)
Anti-4, Month 00.55 (0.45 to 0.67)0.34 (0.25 to 0.45)0.27 (0.22 to 0.33)0.24 (0.19 to 0.3)
Anti-4, Month 113.16 (11.43 to 15.14)11.84 (8.74 to 16.04)4.21 (3.61 to 4.91)6.86 (5.39 to 8.73)
Anti-5, Month 00.55 (0.47 to 0.64)0.06 (0.04 to 0.09)0.4 (0.34 to 0.47)0.04 (0.03 to 0.05)
Anti-5, Month 114.59 (12.53 to 16.99)0.09 (0.06 to 0.13)2.54 (2.11 to 3.06)0.05 (0.04 to 0.06)
Anti-6B, Month 00.66 (0.54 to 0.8)0.38 (0.22 to 0.65)0.34 (0.28 to 0.41)0.34 (0.2 to 0.59)
Anti-6B, Month 17.02 (5.83 to 8.45)9.08 (6.5 to 12.7)2.31 (1.93 to 2.75)6.28 (4.18 to 9.44)
Anti-7F, Month 00.9 (0.77 to 1.04)0.05 (0.03 to 0.07)0.58 (0.51 to 0.67)0.03 (0.03 to 0.04)
Anti-7F, Month 112.52 (11.09 to 14.13)0.06 (0.04 to 0.1)4.14 (3.61 to 4.74)0.03 (0.03 to 0.04)
Anti-9V, Month 01.16 (0.98 to 1.37)0.77 (0.59 to 0.99)0.59 (0.5 to 0.7)0.58 (0.47 to 0.71)
Anti-9V, Month 114.42 (12.44 to 16.7)20.31 (15.44 to 26.71)4.63 (4 to 5.36)13.6 (11.12 to 16.62)
Anti-14, Month 01.32 (1.07 to 1.63)1.83 (1.26 to 2.66)0.84 (0.66 to 1.07)1.04 (0.75 to 1.43)
Anti-14, Month 117.07 (14.12 to 20.64)27.42 (20.96 to 35.86)5.93 (4.97 to 7.09)15.51 (12.14 to 19.82)
Anti-18C, Month 01.43 (1.2 to 1.71)0.42 (0.32 to 0.55)0.63 (0.52 to 0.77)0.4 (0.3 to 053)
Anti-18C, Month 139.59 (34.04 to 46.05)12.07 (9.23 to 15.79)10.49 (8.81 to 12.49)9.92 (7.74 to 12.71)
Anti-19F, Month 01.33 (1.08 to 1.64)0.16 (0.1 to 0.26)0.99 (0.81 to 1.22)0.35 (0.2 to 0.61)
Anti-19F, Month 121.25 (18.07 to 24.98)6.61 (4.9 to 8.92)12.23 (9.89 to 15.13)6.01 (4.75 to 7.6)
Anti-23F, Month 00.94 (0.76 to 1.16)0.41 (0.26 to 0.64)0.33 (0.27 to 0.4)0.62 (0.43 to 0.91)
Anti-23F, Month 113.47 (11.38 to 15.94)14.78 (9.45 to 23.11)3.16 (2.61 to 3.83)10.77 (7.19 to 16.12)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
TitersSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
OPA Anti-1, Month 013.2 (10.2 to 16.9)4.6 (3.9 to 5.4)8.5 (7 to 10.5)4.7 (3.8 to 5.8)
OPA Anti-1, Month 11571.6 (1210.7 to 2040)4.9 (4.1 to 5.8)161.4 (120.7 to 215.9)5.4 (4 to 7.4)
OPA Anti-4, Month 040.5 (27.6 to 59.2)18.5 (10 to 34.2)12.5 (8.9 to 17.4)12.4 (6.7 to 22.8)
OPA Anti-4, Month 15035.8 (4214 to 6017.8)4783.5 (3432 to 6667.2)2498.7 (2103.3 to 2968.4)4812.5 (3167.8 to 7311.3)
OPA Anti-5, Month 019.8 (16 to 24.7)4.2 (3.8 to 4.6)10.9 (8.8 to 13.6)4.5 (3.7 to 5.5)
OPA Anti-5, Month 11135.8 (928.5 to 1389.6)4.9 (3.9 to 6)149.1 (115.4 to 192.5)4.3 (3.8 to 4.8)
OPA Anti-6B, Month 097.8 (61.5 to 155.5)56.6 (21.3 to 150.1)9.9 (7.2 to 13.5)23.3 (9.1 to 60.1)
OPA Anti-6B, Month 12896.8 (2247.5 to 3733.8)9302.7 (7187.3 to 12040.8)405.3 (267.4 to 614.3)3547.1 (1500.7 to 8384.5)
OPA Anti-7F, Month 02278.4 (1803.1 to 2879)378.8 (136.9 to 1048)796.3 (582.2 to 1089.1)63.6 (21.3 to 190.1)
OPA Anti-7F, Month 112484 (10750.7 to 14496.8)1407.7 (694.6 to 2852.9)6436.1 (5507.6 to 7521)90.6 (25.2 to 325.5)
OPA Anti-9V, Month 0788 (655.1 to 947.8)666.8 (482.1 to 922.2)380.2 (313.1 to 461.7)247.5 (164.9 to 371.3)
OPA Anti-9V, Month 14842 (4122.7 to 5686.9)7387.8 (5429.2 to 10052.9)3499.9 (2950.8 to 4151.3)6881.4 (4883.6 to 9696.4)
OPA Anti-14, Month 0298.4 (220.1 to 404.7)337.2 (207 to 549.2)179.6 (127.4 to 253.2)236.6 (132.6 to 422.2)
OPA Anti-14, Month 13579.7 (2966.3 to 4319.9)4097.3 (3019.2 to 5560.2)1961.3 (1630 to 2359.8)2939.5 (2022.3 to 4272.7)
OPA Anti-18C, Month 019.8 (15.2 to 25.9)4.5 (3.9 to 5.2)7.8 (6.5 to 9.4)4.5 (4 to 5.2)
OPA Anti-18C, Month 12417.2 (1989.9 to 2936.2)966.5 (607.1 to 1538.6)694 (532.9 to 903.7)612.1 (338.4 to 1107)
OPA Anti-19F, Month 058.6 (45.2 to 76)7.3 (4.5 to 11.8)33.3 (25.7 to 43.2)11.1 (6 to 20.6)
OPA Anti-19F, Month 12016 (1609 to 2526)473.2 (263.5 to 849.9)1059.8 (808.2 to 1389.7)471 (270 to 821.8)
OPA Anti-23F, Month 0948.9 (688.4 to 1308.2)661.9 (312.5 to 1402)301.8 (198.4 to 459)790.6 (326.8 to 1912.6)
OPA Anti-23F, Month 17456.2 (6301.9 to 8822)23177.9 (13235.9 to 40587.7)3427.3 (2727.7 to 4306.3)19943.3 (13473.1 to 29520.5)
SecondaryAntibody Concentrations to Protein D (Anti-PD)

Seropositivity status, defined as anti-PD antibody concentrations ≥100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · EL.U/mL
Antibody Concentrations to Protein D (Anti-PD)
EL.U/mLSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-PD, Month 0573.1 (495.7 to 662.6)136.8 (102 to 183.3)526.8 (427.4 to 649.3)73.8 (58.4 to 93.2)
Anti-PD, Month 14973.9 (4280.2 to 5780)124.1 (92.8 to 166)2769.6 (2308.5 to 3322.7)91.6 (72 to 116.7)
SecondaryAntibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A

Seropositivity status, defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A
μg/mLSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-6A, Month 00.46 (0.36 to 0.6)0.24 (0.14 to 0.4)0.12 (0.1 to 0.14)0.13 (0.08 to 0.2)
Anti-6A, Month 14.07 (3.09 to 5.36)4.57 (2.92 to 7.17)0.84 (0.65 to 1.08)2.54 (1.65 to 3.93)
Anti-19A, Month 00.24 (0.19 to 0.3)0.08 (0.05 to 0.12)0.16 (0.12 to 0.2)0.06 (0.04 to 0.08)
Anti-19A, Month 13.22 (2.46 to 4.21)0.58 (0.37 to 0.91)1.75 (1.27 to 2.43)0.38 (0.25 to 0.58)
SecondaryOpsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A

Seropositivity status, defined as Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A
TitersSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
OPA Anti-6A, Month 0113.6 (73.6 to 175.4)191.4 (89.7 to 408.2)46.8 (30.8 to 71.1)42.2 (19.3 to 92.1)
OPA Anti-6A, Month 1882.8 (665.9 to 1170.3)2563.8 (1689.9 to 3889.4)369.7 (258.5 to 528.8)1394.5 (827.9 to 2348.9)
OPA Anti-19A, Month 05.3 (4.5 to 6.3)5.1 (3.6 to 7.3)5.3 (4.5 to 6.2)4.4 (3.6 to 5.3)
OPA Anti-19A, Month 189.3 (58.9 to 135.4)8.7 (5.4 to 14.2)70.7 (45.3 to 110.4)20.3 (8.8 to 46.8)
SecondaryNumber of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off

The cut-off of the assay was 0.05 μg/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-1, Month 013571228
Anti-1, Month 1136111259
Anti-4, Month 01344312642
Anti-4, Month 11364312543
Anti-5, Month 01351812813
Anti-5, Month 11363112520
Anti-6B, Month 01324012739
Anti-6B, Month 11354212442
Anti-7F, Month 0135131308
Anti-7F, Month 11361712511
Anti-9V, Month 01354213044
Anti-9V, Month 11364312543
Anti-14, Month 01344213043
Anti-14, Month 11364312543
Anti-18C, Month 01354312944
Anti-18C, Month 11364312543
Anti-19F, Month 01343712943
Anti-19F, Month 11364312443
Anti-23F, Month 01324012543
Anti-23F, Month 11364212442
SecondaryNumber of Subjects With Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off

The cut-off for the assay was 8.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
OPA Anti-1, Month 0613453
OPA Anti-1, Month 113451145
OPA Anti-4, Month 083203912
OPA Anti-4, Month 11344311935
OPA Anti-5, Month 0941562
OPA Anti-5, Month 113041141
OPA Anti-6B, Month 093213414
OPA Anti-6B, Month 11344310632
OPA Anti-7F, Month 01332810915
OPA Anti-7F, Month 11363612213
OPA Anti-9V, Month 01354212136
OPA Anti-9V, Month 11344212135
OPA Anti-14, Month 0119399329
OPA Anti-14, Month 11324212036
OPA Anti-18C, Month 0843424
OPA Anti-18C, Month 11334211436
OPA Anti-19F, Month 011779612
OPA Anti-19F, Month 11353911836
OPA Anti-23F, Month 0130379930
OPA Anti-23F, Month 11364212037
SecondaryNumber of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off

The cut-of for the assay was 0.05 μg/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-6A, Month 01283710533
Anti-6A, Month 11334212542
Anti-19A, Month 01242510527
Anti-19A, Month 11354211942
SecondaryNumber of Subjects With Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A ≥ the Cut-off

The cut-off for the assay was 8.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
OPA Anti-6A, Month 082306319
OPA Anti-6A, Month 1127439732
OPA Anti-19A, Month 0142111
OPA Anti-19A, Month 192117412
SecondaryNumber of Subjects With Antibody Concentrations Against Protein D (Anti-PD) ≥ the Cut-off

The cut-off for the assay was 100 ELISA units per milliliter (EL.U/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Antibody Concentrations Against Protein D (Anti-PD) ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-PD, Month 01312811711
Anti-PD, Month 11352312519
SecondaryAnti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations

Seroprotection status, defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · IU/mL
Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations
IU/mLSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-DT, Month 00.258 (0.209 to 0.319)0.17 (0.118 to 0.243)0.188 (0.153 to 0.231)0.126 (0.088 to 0.179)
Anti-DT, Month 17.829 (6.339 to 9.671)4.768 (3.699 to 6.145)8.463 (7.11 to 10.074)4.876 (3.503 to 6.787)
Anti-TT, Month 00.735 (0.629 to 0.858)0.455 (0.314 to 0.66)0.568 (0.432 to 0.748)0.525 (0.29 to 0.951)
Anti-TT, Month 120.979 (18.359 to 23.972)9.703 (8.173 to 11.518)12.171 (9.772 to 15.16)6.719 (4.598 to 9.819)
SecondaryAnti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations

Seroprotection status, defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · μg/mL
Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations
μg/mLSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix™ GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-PRP, Month 05.335 (3.578 to 7.953)6.433 (2.93 to 14.124)1.03 (0.745 to 1.423)0.894 (0.57 to 1.401)
Anti-PRP, Month 1106.004 (79.937 to 140.572)89.376 (55.131 to 144.891)53.386 (34.817 to 81.858)33.656 (19.464 to 58.198)
SecondaryAnti-Bordetella Pertussis (BPT) Antibody Concentrations

Seropositivity status, defined as anti-BPT antibody concentrations ≥ 15 EL.U/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · EL.U/mL
Anti-Bordetella Pertussis (BPT) Antibody Concentrations
EL.U/mLSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-BPT, Month 012.88 (10.86 to 15.28)12.46 (9.32 to 16.65)9.54 (8.34 to 10.91)10 (8.21 to 12.19)
Anti-BPT, Month 1139.51 (123.26 to 157.89)133.45 (110.33 to 161.4)121.73 (103.16 to 143.64)121.76 (91.81 to 161.47)
SecondaryAnti-hepatitis B Surface Antigen (HBs) Antibody Concentrations

Seroprotection status, defined as anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · mIU/mL
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations
mIU/mLSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-HBs, Month 030 (21.1 to 42.8)23.4 (11.5 to 47.7)97.9 (77 to 124.5)113 (55.1 to 231.7)
Anti-HBs, Month 11220.5 (790.6 to 1884)1098.1 (358.4 to 3364.9)4428.7 (2980.3 to 6581)3188.6 (1171.7 to 8677.1)
SecondaryAnti-polio Type 1, 2 and 3 Antibody Titers

Seroprotection status, defined as anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers ≥ 8.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Geometric mean · Titers
Anti-polio Type 1, 2 and 3 Antibody Titers
TitersSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix™ GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-Polio 1, Month 0329.1 (214.9 to 504.1)269 (114.8 to 630.3)46.5 (33.6 to 64.4)51.1 (28.4 to 91.9)
Anti-Polio 1, Month 1854.6 (573.5 to 1273.5)426.9 (166.2 to 1096.7)932.5 (770.5 to 1128.6)727.3 (512.9 to 1059.9)
Anti-Polio 2, Month 0222.6 (171.8 to 288.3)210.4 (115.4 to 383.6)50.2 (36.9 to 68.2)60.8 (33.4 to 110.8)
Anti-Polio 2, Month 1716.9 (487.6 to 1054.1)689.1 (304.8 to 1557.9)1195.7 (977.8 to 1462.2)1206.6 (737 to 1975.4)
Anti-Polio 3, Month 0102.2 (73.9 to 141.5)38.4 (20.3 to 72.9)51.8 (37.4 to 71.7)71.1 (36.2 to 139.5)
Anti-Polio 3, Month 1232.7 (159.6 to 339.4)190.4 (78.2 to 463.6)1464.2 (1128 to 1900.6)1346.2 (857.6 to 2113.2)
SecondaryNumber of Subjects With Anti-Bordetella Pertussis (BPT) With Concentrations ≥ the Cut-off

The cut-off for the assay was 15 EL.U/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-Bordetella Pertussis (BPT) With Concentrations ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-BPT, Month 02810127
Anti-BPT, Month 165255924
SecondaryNumber of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations ≥ the Cut-off

The cut-off for the assay was 0.1 milli-international units per milliliter (mIU/mL).

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-DT, Month 056184915
Anti-DT, Month 165255924
Anti-TT, Month 065246023
Anti-TT, Month 165255824
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off

The cut-off for the assay was 0.15 μg/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-PRP, Month 065255823
Anti-PRP, Month 165255924
SecondaryNumber of Subjects With Anti-PRP Antibody Concentration ≥ the Cut-off

The cut-off for the assay was 1.0 μg/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-PRP Antibody Concentration ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-PRP, Month 056223212
Anti-PRP, Month 165255724
SecondaryNumber of Subjects With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off

The cut-off for the assay was 10 mIU/mL.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-HBs, Month 053136319
Anti-HBs, Month 168196219
SecondaryNumber of Subjects With Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers ≥ the Cut-off

The cut-off for the assay was 8.

Time frame:
Prior to (Month 0) and one month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers ≥ the Cut-off
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-Polio 1, Month 064195619
Anti-Polio 1, Month 168196319
Anti-Polio 2, Month 069215919
Anti-Polio 2, Month 169216319
Anti-Polio 3, Month 065176118
Anti-Polio 3, Month 166206319
SecondaryNumber of Subjects With Vaccine Response to Anti-Bordetella Pertussis (BPT)

Vaccine response for anti-BPT, defined as the appearance of antibodies in subjects seronegative at pre-vaccination, or at least 2-fold increase of pre-vaccination antibody concentrations in those who were initially seropositive at pre-vaccination.

Time frame:
One month after booster vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Response to Anti-Bordetella Pertussis (BPT)
ParticipantsSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
Anti-BPT, S-37154816
Anti-BPT, S+278117

Adverse events

Collected over Solicited local and general symptoms during the 4-day and unsolicited AEs during the 31- day after booster vaccination; serious adverse events (SAEs): throughout the entire study period from Month 0 to Month 6. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group0/280 (0%)6/280 (2.1%)237/280 (84.6%)
Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group1/93 (1.1%)1/93 (1.1%)78/93 (83.9%)
Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group0/285 (0%)14/285 (4.9%)276/285 (96.8%)
Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group0/98 (0%)5/98 (5.1%)92/98 (93.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
GastroenteritisInfections and infestations1/2800/935/2852/98
Internal injuryInjury, poisoning and procedural complications0/2801/930/2850/98
Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2801/930/2850/98
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/2801/930/2850/98
Febrile convulsionNervous system disorders3/2800/931/2850/98
PneumoniaInfections and infestations1/2800/933/2851/98
PharyngitisInfections and infestations0/2800/933/2850/98
AnaemiaBlood and lymphatic system disorders0/2800/930/2851/98
HypoglobulinaemiaBlood and lymphatic system disorders0/2800/930/2851/98
LymphadenitisBlood and lymphatic system disorders0/2800/930/2851/98
Most frequent other events
Most frequent other events
EventSynflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix -HepB/ Hiberix + Poliorix Group
PainGeneral disorders203/28066/93248/28577/98
IrritabilityPsychiatric disorders173/28064/93244/28579/98
PyrexiaGeneral disorders138/28051/93215/28565/98
ErythemaSkin and subcutaneous tissue disorders107/28037/93197/28566/98
SomnolenceNervous system disorders90/28032/93190/28566/98
Decreased appetiteMetabolism and nutrition disorders97/28028/93184/28557/98
SwellingGeneral disorders92/28032/93158/28552/98
PharyngitisInfections and infestations0/2800/934/2856/98
NasopharyngitisInfections and infestations0/2800/9314/2855/98
RhinitisInfections and infestations3/2802/9311/2855/98

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix - HepB/ Hiberix + Poliorix GroupTotal
Geometric mean16.2 ± 0.6616.2 ± 0.5917.2 ± 0.8417.2 ± 0.8816.71 ± 0.90
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix - HepB/ Hiberix + Poliorix GroupTotal
Gender Categorical — Female1334313443353
Gender Categorical — Male1475015155403
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin GroupPrevenar + Tritanrix - HepB/ Hiberix + Polio Sabin GroupSynflorix + Tritanrix -HepB/ Hiberix + Poliorix GroupPrevenar + Tritanrix - HepB/ Hiberix + Poliorix GroupTotal
Geographic ancestry — White - Caucasian / European heritage0028598383
Geographic ancestry — Asian - south east Asian heritage2809300373
08

Study locations

7 sites
  • GSK Investigational Site
    Muntinlupa, 1781, Philippines
  • GSK Investigational Site
    Gdansk, 80-394, Poland
  • GSK Investigational Site
    Lodz, 91-347, Poland
  • GSK Investigational Site
    Trzebnica, 55-100, Poland
  • GSK Investigational Site
    Tuchola, 89-500, Poland
  • GSK Investigational Site
    Wroclaw, 50345, Poland
  • GSK Investigational Site
    Wroclaw, 52-312, Poland
09

References and documents

Publications

  • Bermal N, Szenborn L, Edison A, Hernandez M, Pejcz J, Majda-Stanislawska E, Gatchalian S, Fanic A, Dieussaert I, Schuerman L. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr Infect Dis J. 2011 Jan;30(1):69-72. doi: 10.1097/INF.0b013e3181f2da06. PubMed 20980933 ↗
  • Bermal N et al. Primary and booster vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) co-administered with DTPw-HBV/Hib and polio vaccines. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.
  • Nancy B et al. Booster dose of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) administered to children in the Philippines: antibody responses and safety. Abstract presented at the 13th Asian Pacific Congress of Pediatrics (APCP). Shanghai, China, 14-18 October 2009.
  • Schuerman L et al. Immune responses against cross-reactive pneumococcal serotypes 6A and 19A with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.
  • Schuerman L et al. Immune responses to the non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) appear not influenced by co-administration with DTPw-combination vaccine. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2007 to primary completion in May 2008, 6 months.

Results were first posted in Jan 2019, 10 years 8 months after primary completion. A results delay was requested in May 2009.

Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 6 months is below that.

Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2007
First posted
Oct 22, 2007
StartActual
Oct 22, 2007
Primary completionActual
May 10, 2008
CompletionActual
Oct 7, 2008
Results delay requested
May 20, 2009
Results first posted
Jan 14, 2019
Last update
Jan 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00547248
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 22, 2007
Start date
Oct 22, 2007
Primary completion
May 10, 2008
Completion
Oct 7, 2008
Results posted
Jan 14, 2019
Last update
Jan 14, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PHiD-CV vaccine · Poliovirus Vaccine, Oral · Poliovirus Vaccine, Inactivated

Start the discussion